Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 2/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | PER2 | O15055 | 8/20 | 0.33 |
| ▸ | CRY1 | Q16526 | 8/20 | 0.33 |
| ▸ | CRY2 | Q49AN0 | 8/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753836 | 0.94 | ALOX5 (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1911460 | 0.88 | L3MBTL1 (0.36) | PER2CRY1CRY2L3MBTL1 | |
| SCHEMBL12251949 | 0.87 | PER2 (0.34) | PER2CRY1CRY2 | |
| SCHEMBL23921620 | 0.86 | ALOX5 (0.37) | PER2CRY1CRY2L3MBTL1 | |
| SCHEMBL18591638 | 0.81 | CRY1 (0.36) | PER2CRY1CRY2 | |
| SCHEMBL728955 | 0.81 | PER2 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1486529 | 0.79 | PER2 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18591647 | 0.79 | PER2 (0.35) | PER2CRY1CRY2 | |
| SCHEMBL28527867 | 0.79 | PER2 (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL17556101 | 0.79 | PER2 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340158-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (CN) | 2021-11-04 | — | — | US | disclosed |
| EP-3139436-B1 | ELECTROLYTE AND LITHIUM BATTERY INCLUDING THE ELECTROLYTE | SAMSUNG SDI CO LTD (KR) | 2019-06-19 | — | — | EP | disclosed |
| US-20160068531-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068531-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | ZC3HAV1, IDO1, AZI2 | PSEN1 3304/4885PSEN2 3968/4885APH1B 4174/4885 |
| US-20210340158-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | MCL1, BCL9, BCL9L | PSEN1 3777/4885PSEN2 4579/4885APH1B 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.